ArticleThe American journal of case reports2025
Acute Kidney Injury After Accelerated Dosing of Tirzepatide in a Patient with Multiple Comorbidities: A Case Report.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis.International journal of molecular sciences · 2026Article
- Adverse events associated with tirzepatide: a focus on subgroup-specific differences.BMC pharmacology & toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Tirzepatide is effective for glycemic control and weight management in type 2 diabetes and obesity. Clinical trials have demonstrated tirzepatide's lower risk of acute kidney injury (AKI) compared with existing glucagon-like peptide-1 receptor agonists, along with benefits including reduced albuminuria and stable estimated glomerular filtration rate. Rare cases of AKI have been reported, potentially associated with dehydration from gastrointestinal side effects, polypharmacy, or comorbidities. We describe AKI in a non-diabetic, multimorbid patient after rapid tirzepatide dose escalation, underscoring the importance of identifying susceptible patient phenotypes. CASE REPORT A 66-year-old man with morbid obesity (body mass index 61.4 kg/m²), hypertension, prediabetes, hypothyroidism, and polypharmacy presented for weight management before bariatric surgery. Tirzepatide was initiated at 2.5 mg weekly and escalated to 12.5 mg over 4 months, resulting in weight loss of 35 kg. Preoperative evaluation revealed AKI, with a serum creatinine level of 2.4 mg/dL, potassium of 6.8 mmol/L, and metabolic acidosis (pH 7.31). Potential contributors included pharmacodynamic interactions with antihypertensive agents or dehydration secondary to gastrointestinal side effects. Management involved intensive care unit admission, antihyperkalemic therapy, intravenous fluids, and tirzepatide discontinuation. Renal function improved (creatinine 1.18 mg/dL) by discharge. CONCLUSIONS The AKI in this case may have resulted from the combination of rapid tirzepatide dose escalation, polypharmacy, and multimorbidity, potentially compounded by subclinical volume depletion or hemodynamic alterations. Clinicians should utilize standard titration schedules, closely monitor blood pressure and renal function, and exercise caution in patients with complex medication regimens to maximize tirzepatide's therapeutic benefits while minimizing renal risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.